Ascendis Pharma A/S (A71)
XBER 
Summary
A71 Chart
Ascendis: Q3 Results Validate The TransCon Platform
Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and strong Q3 2025 revenues of €213.6 million. ASND's robust cash position (€539 million) and self-sustaining business model eliminate near-term dilution risk and support continued pipeline investment. TransCon platform advances, including SKYTROFA label expansion and TransCon CNP, offer significant growth opportunities, with regulatory risk now mostly administrative.
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Chad Fugere Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smith - CFO, Executive VP & Member of Executive Board Jay Wu - Executive VP & President of Ascendis US Aimee Shu - Executive VP & Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Yaron Werber - TD Cowen, Research Division Martin Auster - Raymond James & Associates, Inc., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yun Zhong - Wedbush Securities Inc., Research Division Charles Ndiaye - Stifel, Nicolaus & Company, Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Maxwell Skor - Morgan Stanley, Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the Third Quarter 2025 Ascendis Pharma Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Chad Fugere, Vice President of Investor Relations at Ascendis Pharma.
Ascendis Pharma A/S (A71) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Ascendis Pharma A/S ever had a stock split?
Ascendis Pharma A/S Profile
| - Industry | - Sector | Jan Moller Mikkelsen CEO | XBER Exchange | US04351P1012 ISIN |
| DK Country | 1,017 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Ascendis Pharma A/S is an innovative biopharmaceutical company that dedicates its efforts to addressing unmet medical needs through the development of groundbreaking therapies. Founded in 2006 and headquartered in Hellerup, Denmark, the company has established itself as a leader in the field of biopharmaceuticals, particularly focusing on rare diseases within endocrinology and oncology. Ascendis Pharma leverages its proprietary technology and deep scientific expertise to create therapies that aim to significantly improve patients' lives across the globe.
Products and Services
- SKYTROFA
Ascendis Pharma's SKYTROFA is a pivotal drug designed for the treatment of growth hormone deficiency (GHD) in patients. This therapeutic solution represents the company's commitment to addressing the challenges faced by individuals dealing with GHD, offering them a potentially transformative treatment option.
- Endocrinology Rare Disease Product Candidates
The company is developing a rich pipeline of three independent rare disease product candidates within the endocrinology domain. These are currently in clinical development stages, showcasing Ascendis Pharma's focused endeavor to bring novel treatments to patients suffering from rare endocrine disorders.
- Oncology Therapeutic Candidates
In addition to its work in endocrinology, Ascendis Pharma is actively advancing therapeutic candidates in the field of oncology. This effort demonstrates the company's dedication to extending its impact beyond endocrinology and into other areas where there are substantial unmet medical needs, particularly in the treatment of various cancers.
Contact Information
